Arvinas announced CEO John Houston will retire after over eight years steering the company, as its lead PROTAC (proteolysis-targeting chimera) protein degrader program nears a critical development phase. The company, a pioneer in targeted protein degradation therapeutics, has made recent advances including clinical trial progress. Houston’s leadership spanned Arvinas’ evolution from early-stage biotech to a clinical-stage program holder. The departure signals a leadership transition at a key juncture for the PROTAC modality’s maturation and the firm's growth trajectory.